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the validated source model. The MC simulations were done using the 
original treatment parameters; source strength, dwell positions and 
times. The MC dose metrics for PTV and skin D90 and D0.1cc were 
compared to the TG-43 treatment plan. 
Results: A validation simulation using a water-based geometry agreed 
to within 1% of the treatment plan's D90. The patient dose was scored 
in terms of dose to water in medium (Dw,m) and compared against the 
TG-43 plan (Dw,w) (figure). All dose metrics demonstrate a decrease in 
Dw,m compared to Dw,w on the order of 10-30%. The TG-43 D90 is 
reduced by 20% in Dw,m. The D0.1cc for the skin showed a 30% reduction 
when recalculated in MC. The reduction is the result of a complex 
combination of factors such as tissue heterogeneity, loss of 
backscatter at the skin/lung interface and the applicator design, in 
particular the wall of the balloon applicator which reduces the dose 
fluence by approximately 7% due to the presence of barium sulfate (a 
high-Z compound).  
 
  
Figure: Top Right: Isodose comparison of MC-based(solid lines) versus 
TG-43-based dosimetry (dashed lines) Bottom: Ratio of Dw,w to Dw,m. 
Black lines denotes PTV. Dw,m to air/lung is reported as zero. Top left: 
HU-based tissue segmentation of the breast. 
 
Conclusions: Results indicate that effects of under-dosing on the dose 
distribution for Dw,m compared to Dw,w. This study demonstrates the 
need for more comprehensive dosimetry model to the current TG-43 
dose formulation.  
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Purpose/Objective: Model based dose calculation algorithms 
(MBDCAs), recently introduced in treatment planning systems for 
brachytherapy (BT), calculate absorbed doses to the medium (i.e. to 
the tissues). The aim of this work was to shed light on the yet 
unresolved issue of which method for converting absorbed dose to 
medium Dm,m into absorbed dose to water Dw,m is most suitable for BT. 
'Small cavity theory' implies conversion by stopping power ratios and is 
applicable when ranges of secondary electrons are long compared to 
cavity dimensions while 'large cavity theory' implies conversion by 
ratios of mass energy absorption coefficients and is applicable when 
ranges are short in relation to cavity dimensions. The relationship 
between cavity size and applicable cavity theory at the photon 
energies of interest to BT, i.e., in the energy range 20-1000 keV, was 
investigated. An argument in favor of reporting Dw,m has been that 
there exists a radiotherapy target being of cellular dimensions that is 
more water-like in all tissues than the average bulk medium obtained 
from CT images and used in MBDCA calculations. 
Materials and Methods: Burlin cavity theory was applied to estimate 
photon energies at which cavity sizes in the range 1 nm -10 mm can 
be considered small or large. Photon- and electron energy spectra 
were calculated at 1 cm distance from the central axis in phantoms of 
bone, muscle and adipose tissue for centrally placed 20, 50, 300 keV, 
125I, 169Yb and 192Ir photon point sources; ratios of mass collision-
stopping powers and mass energy absorption coefficients were 
calculated as applicable to convert Dmed into Dw,med for small and large 
cavities.  
Results: The figure shows the parameter d in the Burlin theory as 
function of photon energy and cavity size; a cavity is small when d is 
close to unity and large when d is close to zero.  
1-10 nm sized cavities are small at all investigated photon energies; 
100 μm cavities are large only at photon energies < 20 keV and 
cavities of mm dimensions are required for large cavity theory to be 
suitable at 192Ir photon energies around 300 keV.  
 Conclusions: The question whether to report Dm,m or Dw,m arises when 
using MBDCAs for BT similar to in external beam therapy. However in 
BT the additional problem of deciding appropriate cavity dimensions 
arises due to the short ranges of secondary electrons. Free radicals 
from DNA bound water of nm dimensions contribute to complex DNA 
damage and cell killing and may be the most important water 
compartment in cells which would imply use of ratios of mass-collision 
stopping-powers for converting Dm into Dw,m in BT as used in external 
beam therapy. Stopping power ratios vary little with energy and lead 
to numerical values for Dw,m/Dm,m similar to those reported for other 
radiotherapy modalities. Mass energy absorption coefficient ratios 
imply large differences in Dm /Dw,m over the BT energy range and to 
those obtained in external beam therapy. 
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Purpose/Objective: To analyse late urogenital (UG), gastrointestinal 
(GI) and vaginal (VG) morbidity in patients treated for cervical cancer 
by IGABT in a multicentre setting. 
Materials and Methods: RetroEMBRACE is a retrospective collection of 
data from patients treated for cervical cancer by IGABT using the 
GEC-ESTRO guidelines. At present, 796 patients have been registered 
from 12 institutions. Detailed data on morbidity grade 1-5 (CTCAE, 
V3.0) has been entered in 533 patients from 5 institutions. In these 
patients, FIGO-stage was IB1-IIA/IIB/IIIA-IVAB in 28%/48%/24%. Eighty-
four percent were squamous cell carcinomas. In all patients IGABT 
was preceded by 3D conformal radiotherapy or Intensity Modulated 
Radiotherapy with mean dose of 46 ±3 Gy in 26 ±2 fractions and 
weekly concomitant cisplatinum in 76%. A nodal boost of 57 ±3 Gy was 
given to 16% and a parametrial boost of 55 ±2 Gy was given to 4%. 
